BridgeBio Pharma
BBIO
BBIO
88 hedge funds and large institutions have $3.67B invested in BridgeBio Pharma in 2019 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 31 increasing their positions, 16 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
17% more funds holding
Funds holding: 75 → 88 (+13)
1.71% less ownership
Funds ownership: 88.47% → 86.77% (-1.7%)
Holders
88
Holding in Top 10
7
Calls
–
Puts
–
Top Buyers
| 1 | +$94.2M | |
| 2 | +$41.5M | |
| 3 | +$19.2M | |
| 4 |
State Street
Boston,
Massachusetts
|
+$16M |
| 5 |
Nuveen Asset Management
Chicago,
Illinois
|
+$15.7M |
Top Sellers
| 1 | -$24.9M | |
| 2 | -$15.6M | |
| 3 | -$8.93M | |
| 4 |
DM
Deerfield Management
New York
|
-$6.23M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.67M |